Key Highlights
- Third quarter loss per share was USD 0.74 against an estimated USD 0.67 loss, with no Revenue reported.
- Cash, equivalents and marketable securities were USD 700.5 million, guided to fund operating expenses and capital expenditures through 2030.
- Research and development expense was USD 43.1 million for the quarter, up from USD 25.5 million a year earlier.
- In SURF302, the 60 mg cohort showed a 79% overall response rate among 14 evaluable participants.
Tyra Biosciences (NASDAQ:TYRA), a clinical-stage precision oncology company, reported a third quarter 2026 loss of USD 0.74 per share, wider than the USD 0.67 estimated loss. The company has not generated revenue. Net loss for the nine months was USD 136.0 million, against USD 86.1 million a year earlier, and the accumulated Deficit was USD 507.2 million.
Research and development expense was USD 43.1 million, up USD 17.6 million, driven by a USD 9.1 million increase in external costs for dabogratinib trials and an USD 8.1 million increase in personnel costs from headcount growth. General and administrative expense was USD 11.7 million, up from USD 7.5 million.
Cash and Runway
Cash, cash equivalents and marketable securities were USD 700.5 million at September 30, 2026. Based on its current operating plan, the company states its resources are sufficient to fund operating expenses and capital expenditures through 2030. It has funded operations mainly through sales of common stock and pre-funded warrants and says it expects continued increases in operating losses as it advances its programs.
Dabogratinib Across Three Phase 2 Trials
The lead program is oral dabogratinib, designed to be more selective for FGFR3 than for other FGFR family members. It has been administered to over 200 individuals. The company runs three Phase 2 trials under what it calls its 3x3 strategy.
SURF303 evaluates low-grade upper tract urothelial carcinoma in an open-label Phase 2a/b design at 60 mg and 80 mg once daily. In September 2026 the company announced the first patient treated achieved a complete response at the three-month assessment.
SURF302 evaluates low-grade intermediate-risk non-muscle invasive bladder cancer at 50 mg and 60 mg. As of an August 31, 2026 data cutoff, grade 3 treatment-related adverse events occurred in 2 of 44 participants, both at 50 mg, with none at 60 mg and no grade 4 or 5 events. Among 14 evaluable participants at 60 mg, the overall response rate was 79% (11 of 14) and the complete response rate was 64% (9 of 14). The company noted responses may change with continued treatment. It has completed enrollment in the 60 mg cohort and is enrolling a 70 mg cohort, and it plans to engage health authorities on Phase 3 design, with a registrational adjuvant study scheduled to start in 2027.
BEACH301 evaluates children aged 3 to 10 with achondroplasia in a dose-escalation trial. The study has advanced through five dose levels and a sixth, 0.875 mg/kg, was authorized to open. Initial results including six-month annualized height velocity are scheduled to be reported in 2027 from about 25 children.
Markers to Follow
The 2027 achondroplasia readout, the Phase 3 design discussions in bladder cancer and growth in research spending are the items to follow. Early efficacy figures come from small cohorts and can change as follow-up continues.






Please wait processing your request...